MUC1 is a highly immunogenic epithelial mucin and serves as a tumor-associated antigen in breast, pancreatic and ovarian carcinomas. We previously reported the expression of MUC1 on myeloma cells and the establishment of an HLA-unrestricted cytotoxic T lymphocyte (CTL) line TN that recognized MUC1 from peripheral blood mononuclear cells in a multiple myeloma patient. In this study, we attempted to induce such CTL from six other multiple myeloma patients consecutively in order to show that the induction of the CTL line TN had not resulted from some idiosyncrasy of the first patient. Bone marrow mononuclear cells were used to induce CTL, because they contain myeloma cells that might stimulate the autologous lymphocytes. Bulk CTL lines were induced from two out of six patients. The CTL line TS was CD8 ⍣ cell dominant and KY was CD4 ⍣ cell dominant. Both CTL lines lysed MUC1 ⍣ myeloma and breast carcinoma cell lines. The cytotoxicity of the CTL lines was inhibited by anti-CD3, anti-αβ TCR and anti-MUC1 mAb. It was also inhibited by a MUC1 transfectant, but not by a mock transfectant in cold target inhibition assays. MUC1 was transfected into a human colonic carcinoma cell line. The reactivity of anti-MUC1 core protein mAb and the cytotoxicity of the CTL against the transfectant was enhanced by the treatment of the cells with an O-glycosylation inhibitor. Thus it is generally accepted that the HLA-unrestricted CTL which directly recognize the underglycosylated form of MUC1 using their TCR could be induced from a certain proportion (~30%) of untreated multiple myeloma patients.
Introduction
MUC1 is a mucin molecule produced by ductal epithelial MUC1 is highly immunogenic-autoantibodies against it have been detected not only in sera of cancer patients but cells of a variety of tissues and also by tumors derived from these tissues. It is a type I transmembrane glycoprotein with also in sera of ulcerative colitis patients (5-7). Moreover, CTL against MUC1 have also been induced in pancreas, breast unique extracellular domains mostly consisting of tandem repeats of 20 amino acids (1) (2) (3) . The number of tandem and ovarian cancer patients (8-10). Interestingly, these CTL directly recognized MUC1 molecules in an HLA-unrestricted repeats is 25-100 or more and varies among individuals or derived tissues. MUC1 contains a lot of O-linked glycosylation manner unlike conventional CTL. It was proposed that normally cryptic CTL epitopes on the MUC1 core protein were sites, and the level of glycosylation varies among different tissues and between normal and malignant cells. The cytounmasked by underglycosylation in tumor cells and the highly multivalent epitopes of tandemly repeated peptides on a plasmic tail of MUC1 contains tyrosine phosphorylation sites and tyrosine phosphorylated MUC1 directly interacts with the single MUC1 molecule cross-linked the TCR of anti-MUC1 CTL. SH2 domain of the adaptor protein Grb2 (4) . It has thus been suggested to have a role in intracellular signaling.
MUC1 was also detected in non-epithelial cells as epithelial membrane antigen (EMA), especially in lymphoid malignanabove supplemented with heat-inactivated human AB serum instead of FCS. We did not add tumor cells in initial culture cies (11). We previously reported the expression of MUC1 on myeloma cells and the detection of circulating MUC1
because contaminating myeloma cells could be stimulator cells for lymphocytes. Three days after the onset of the molecules in~50% of our multiple myeloma patients (12). We have established an anti-myeloma CTL line TN from peripheral culture, recombinant IL-2 (a gift from Takeda Pharmaceutical, Osaka, Japan) was added at a final concentration of 5 IU/ml. blood mononuclear cells (PBMC) in a stage III multiple myeloma patient. TN recognized MUC1 in an HLA-unrestricted
The cultured cells were stimulated with RPMI8226 cells at a lymphocyte:stimulator ratio of 20:1 on day 7. A different tumor manner. This suggested that the precursors of HLA-unrestricted CTL reacting with MUC1 could exist in multiple myeloma cell line was used for the second stimulation in order to minimize the induction of allo-reactive T cells. The cells were patients, though the supposition that the CTL line was accidentally induced because of some idiosyncrasy of that patient re-stimulated on day 14 with MDA-MB-231, on day 21 with KR12 and on day 28 with RPMI1788. Cell culture was is a possibility which still has to be eliminated. Moreover, a more efficient way to induce the CTL from multiple myeloma expanded in proportion to proliferation of the lymphocytes. The lymphocytes used in this study were Ͼ4 weeks old patients will be required if this is to be used clinically in immunotherapy for multiple myeloma on the basis of antigrown in vitro. Tumor cell lines were treated with mitomycin C (50 mg/ml; Sigma, St Louis, MO) at 37°C for 30 min and MUC1 immunity.
To address these issues, we performed allogeneic mixed washed three times with culture medium before use. leukocyte tumor cell culture (MLTC) to induce the CTL in six Cell-mediated cytotoxicity assay consecutive non-treated multiple myeloma patients, with bone marrow mononuclear cells instead of PBMC as a source of Cell-mediated cytotoxicity was assessed with 51 Cr release assay as previously described (12). Briefly,~1ϫ10 6 target MLTC in this study. We expected that bone marrow mononuclear cells would be the better source because they cells were suspended in 1 ml of culture medium and labeled with 100 mCi of 51 Cr (New England Nuclear, Boston, MA) for contained myeloma cells that might stimulate the autologous lymphocytes. Moreover, it was also expected that the bone 45-60 min at 37°C and washed three times. Then 5ϫ10 3 labeled cells were seeded into each well of 96-well marrow lymphocytes might be pre-sensitized by myeloma cells more often than peripheral blood lymphocytes. CTL U-bottomed tissue culture plates (Costar, Cambridge, MA). Effector cells were added at various E:T ratios and assays were consequently induced in two out of six myeloma patients. These CTL showed HLA-unrestricted cytotoxicity and their were performed in triplicate. The plates were incubated for 4 h at 37°C in a 5% CO 2 atmosphere. Supernatants were target molecule appeared to be MUC1. Moreover, we showed exposure of the CTL epitope on MUC1 by an O-glycosylation harvested with a Skatron harvesting system (Skatron, Stering, VA) and assayed in a γ-counter. Percent specific lysis was inhibitor, with the cytotoxicity being markedly enhanced. These findings may confer meaning in the design of immunocalculated as: (experimental release -spontaneous release)/ (maximum release -spontaneous release)ϫ100. Spontherapy of multiple myeloma. were added. Cytotoxicity was assessed as described above. JRST and Kato III are gastric carcinoma cell lines. CHCY1
Percent inhibition was calculated as: (% specific lysis without and DLD-1 are colonic carcinoma cell lines. RPMI8226, KR4, cold target -% specific lysis with cold target)/(% specific KR12 and TAPC were myeloma cell lines. RPMI1788 is a B lysis without cold target)ϫ100. cell line. CEM is a T cell line. K562 is an erythroleukemic cell Antibodies line. EJ-NIH-3T3 is a mouse fibroblast cell line transfected with human activated H-ras gene. mAb T4 (anti-CD4), mAb T8 (anti-CD8) and MSIgG (control MUC1 ϩ -EJ-NIH-3T3 is a sense MUC1 gene transfectant antibody) were obtained from Coulter Immunology (Hialeah, and MUC1 --EJ-NIH-3T3 is an anti-sense MUC1 gene tranfect-FL). mAb UCHT1 (anti-CD3), W6/32 (anti-HLA class I), DK22 ant as previously described (12). HLA allelic typing of tumor (anti-HLA DR) and E29 (anti-EMA; anti-protein core epitope of cell lines was performed by PCR-RFLP, PCR-SSOP or PCR-MUC1) were purchased from Dakopatts (Glostrup, Denmark). SSP methods at the Shionogi Biomedical Laboratory, Osaka, mAb MUSE11 recognizes a protein core epitope of MUC1 Japan as described elsewhere (13-17).
(18) and was purified using a Protein A column (MAPS II system; BioRad, Richmond, CA). mAb against CD16, αβ TCR Establishment of CTL lines and γδ TCR were obtained from T cell Science (Boston, MA). mAb TCR Pan αβ used for the blocking assay was purchased Mononuclear cells of six consecutive multiple myeloma patients were separated from heparinized bone marrow blood from Immunotech (Marseille, France). For target blocking assays, antibodies W6/32, DK22, by Ficoll-Paque (Pharmacia, Pisctaway, NJ). Bone marrow mononuclear cells were cultured in the medium described MUSE11, E29 or MSIgG were added to the wells in which 51 Cr-labeled target cells had been seeded. The effector cells and against a B cell line. KY cells showed less broad activity, though one of three breast carcinoma cell lines and three of were added after the plates had been incubated for 30 min at room temperature. For effector blocking assays, mAb three myeloma cell lines were lysed. All the cell lines lysed by the CTL lines expressed MUC1 mucin as judged by mAb UCHT1, TCR Pan αβ, T4, T8 or MSIgG were added to the wells in which lymphocytes had been seeded. The target (data not shown). HLA-allelic typing of the tumor cell lines lysed by the CTL disclosed no apparent HLA-A, -B, -C or cells were added after the cells had been incubated for 30 min at room temperature. Then the cytotoxicity assays were -DR restriction (Table 2) . NK/LAK cell-sensitive K562 cells were not killed by either TS or KY cells at all, thus the broad performed as described above.
For determination of cell surface phenotype of TS and KY reactivity of these CTL lines is not explained by a non-specific NK/LAK cell-like activity. cells, indirect immunofluorescent assays were performed as previously described (19). Briefly, cells were incubated with Cell surface phenotypes of the CTL lines were analyzed by flow cytometry (Fig. 1) 
Establishment of MUC1-transfected cells and inhibition of
Characterization of lysis mediated by the CTL glycosylation with benzyl-α-GalNAc
Blocking assays using mAb were performed to investigate Transfection of MUC1 gene into a human colonic carcinoma the mechanism of recognition of target cells. As shown in Fig.  cell line CHCY1 was performed as previously described (12).
2(A and C), the cytotoxicity of TS and KY cells was inhibited A mammalian expression vector pHβAPr-1-neo containing the by an anti-CD3 mAb, though no significant inhibition by an full-length MUC1 cDNA (20) and a vector containing antisense anti-CD4 mAb nor by an anti-CD8 mAb were observed in MUC1 cDNA were kindly provided by Dr Richard S. Metzgar, effector blocking assays. In target blocking assays, no definite Duke University. Liposome-DNA mixture was made of 20 µg inhibition by anti-HLA mAb were observed ( Fig. 2B and D) . of the plasmid DNA and 60 µl of Transfectace (Gibco/BRL, These results were in agreement with our previous report Grand Island, NY) in 6 ml of DMEM. CHCY1 cells were about the HLA-unrestricted CTL line TN. Together with the washed twice with DMEM and then incubated with 6 ml of HLA-allelic typing DATA, HLA is not likely to be the target the liposome-DNA mixture over night. Then, 6 ml of DMEM molecule recognized by TS and KY cells. supplemented with 20% FCS (v/v) was added and the cells Both CTL lines were considered to have used their CD3-were incubated for 24 h. The media were then replaced with TCR complex for recognition of the target antigen. The TCR DMEM with 10% FCS (v/v) and they were then incubated for usage of TS cells was confirmed by a separate experiment another 72 h. G418 (Geneticin; Gibco/BRL) was added in the using an anti-αβ TCR mAb (Fig. 3) . The cytotoxicity of TS culture at a concentration of 800 µg/ml. The transfectants cells was clearly inhibited by an anti-αβ TCR mAb as well as were cloned by limiting dilution. MUC1 ϩ -CHCY1 is a sense by an anti-CD3 mAb in a dose-dependent manner. MUC1 gene transfectant and MUC1 --CHCY1 an anti-sense MUC1 gene tranfectant.
Target antigen for TS and KY cells For inhibition of glycosylation, MUC1 ϩ -CHCY1 cells and
To investigate the target molecule of the CTL lines, an MUC1 --CHCY1 cells were incubated in 10% FCS/RPMI 1640 H-ras-transformed mouse fibroblast cell line, EJ-NIH-3T3, was supplemented with 5 mM benzyl-GalNAc (Sigma) for 5 days.
transfected with a sense MUC1 gene and an anti-sense Benzyl-GalNAc is a competitive inhibitor of mucin glycosyl-MUC1 gene. We anticipated that accidental HLA matching ation (21) .
would be precluded by using the mouse cell line. LAK cells equally killed both the transfectants (data not shown). Thus, Results the transfection of the MUC1 gene did not affect the susceptibility of the cells to non-specific effector cells. TS cells showed Establishment and characterization of CTL lines TS and KY significant cytotoxicity against MUC1 ϩ -EJ-NIH-3T3, but only marginal cytotoxicity was observed against MUC1 --EJ-NIHBone marrow lymphocytes stimulated with allogeneic MUC1-positive cells proliferated for at least 3 weeks, though four 3T3 (Fig. 4A) . Thus, MUC1 is considered to be the target molecule of TS cells. The cytotoxicity of TS cells against the out of six cultured cells declined in number after having been cultured for a longer time. Two out of six cultured cells myeloma cell line RPMI8226 was clearly inhibited by MUC1 ϩ -EJ-NIH-3T3, but not by MUC1 --EJ-NIH-3T3, in cold target proliferated up until 10 weeks, and the CTL lines TS and KY were established. The analysis of KY cells was limited because inhibition assays (Fig. 4B) . Therefore, TS cells can recognize myeloma cells through the MUC1 molecule. we could not obtain sufficient CTL from the small number of initially cultured bone marrow cells.
As shown in Fig. 4(C) , KY cells did not lyse either MUC1 ϩ -EJ-NIH-3T3 or MUC1 --EJ-NIH-3T3. As the cytotoxicity of KY Cytotoxicity of TS and KY cells was investigated using a panel of human tumor cell lines (Table 1) . TS cells showed cells against RPMI8226 was clearly inhibited by MUC1 ϩ -EJ-NIH-3T3 but not by MUC1 --EJ-NIH-3T3 (Fig. 4D) ; however, definite cytotoxicity against two of three breast carcinoma cell lines, four of four myeloma cell lines, two of two gastric KY cells also appeared to be able to recognize MUC1 on myeloma cells. carcinoma cell lines, two of two colonic carcinoma cell lines A blocking assay of TS cells was also performed using Discussion anti-MUC1 mAb. As shown in Fig. 5 , anti-MUC1 mAb MUSE11
A lot of studies have indicated that the immune repertoire of and E29 clearly inhibited the cytotoxicity of TS cells; the cancer patients contains B and T cells that recognize antigens epitope of the CTL was thus considered to exist in the protein expressed by autologous cancer cells. Recently, several core of MUC1.
genes encoding human tumor rejection antigens of melanoma Inhibition of glycosylation affects recognition by antibody and breast carcinoma have been identified (22). Those antiand CTL gens were presented by HLA class I molecules as short peptides and recognized by autologous CD8 ϩ CTL. Several The MUC1 gene was transfected into a human colonic studies to identify the epithelial tumor rejection antigens are carcinoma cell line CHCY1 which expressed MUC1 weakly.
currently under progression (23-25). As shown in Fig. 6 , MUC1 ϩ -CHCY1 cells showed only a
In hematological malignancies, only a few studies have minor augmentation of reactivity to an anti-MUC1 mAb when been performed to suggest the existence of tumor rejection compared to MUC1 --CHCY1 cells. When the MUC1 ϩ -CHCY1 antigens recognized by CTL (26) (27) (28) . Graft-versus-tumor cells were treated with O-glycosylation inhibitor benzyl-α-responses without graft-versus-host disease by infusion of GalNAc, reactivity of the mAb was strongly increased.
donor leukocytes in relapsed leukemia and myeloma patients We then investigated the cytotoxicity of TS cells against after bone marrow transplantation were reported (29) (30) (31) . This these above cells to see the effect of O-glycosylation inhibitor.
was circumstantial evidence supporting the existence of tumor As shown in Fig. 7 , susceptibility of lysis by TS cells was rejection antigens in hematological malignancies. strikingly augmented by the O-glycosylation inhibitor treatIn the previous study, we established an HLA-unrestricted ment of the MUC1 transfectant. On the contrary, no such CTL line TN which reacted with MUC1 from peripheral blood enhancement of lysis was observed in the mock transfectant.
of a multiple myeloma patient with a large tumor burden. As Therefore increase in cytotoxicity could not be due to general far as we know, no other defined tumor-associated antigens cytotoxic effects of benzyl-α-GalNAc. The susceptibility of the cells seemed almost parallel to the reactivity to the mAb.
recognized by CTL in multiple myeloma have been reported. consecutive untreated multiple myeloma patients to eliminate the possibility that such CTL could have been accidentally induced by an idiosyncratic immune response of the previous patient. Two CTL lines designated as TS and KY were T cells in bone marrow mononuclear cells of multiple myeloma patients have recently been shown to possess distinct features successfully induced from the bone marrow mononuclear cells. The CTL lines showed broad cytotoxicity against MUC1-in terms of susceptibility to CD3 stimulation and cytokine production compared with normal bone marrow T cells and positive tumor cell lines regardless of the cell type, with the exception of K562 cells which are sensitive to NK/LAK cells. this could be exploited to generate anti-plasma cell activity (32) . In this study, we therefore used bone marrow monoThe cytotoxicities were not restricted by HLA-A, -B, -C or -DR have used their CD3-TCR complex for recognition of the target antigen. However, the contribution of not only TCR but other molecules (CD2, LFA-1 or other adhesion molecules) should be also considered because it is possible that the antibody treatment inhibited the signal from other molecules which bind to MUC1.
Treatment of MUC1-transfected Epstein-Barr virus-transformed B cells or normal mammary epithelial cells using O-glycosylation inhibitor phenyl-GalNAc or benzyl-GalNAc resulted in the exposure of tumor-associated epitopes recognized by anti-MUC1 protein core mAb (33, 34 ) and MUC1 transfected Epstein-Barr virus-transformed B cells treated with the inhibitor became more susceptible to an anti-MUC1 CTL clone than the non-treated cells (35) . We also investigated the effect of an O-glycosylation inhibitor on the recognition of MUC1 by the CTL. In this study, we transfected the MUC1 gene into the colon cancer cell line CHCY1. Treatment of the transfectant with O-glycosylation inhibitor benzyl-GalNAc resulted in marked enhancement of reactivity with an anti-MUC1 mAb. Thus, MUC1 in CHCY1 cells is considered to be highly glycosylated and most of the core protein epitopes cytotoxicity against the myeloma cell line RPMI8226 was clearly inhibited by the MUC1 transfectant in a cold target inhibition assay. CD4 ϩ CTL preferentially lyse their targets via Fas-Fas ligand interaction, whereas the major cytotoxic effect as judged by HLA-allelic typing. The cytotoxicities of both CTL lines were not inhibited by anti-HLA mAb. Anti-MUC1 of CD8 ϩ CTL is by perforin and granzymes (36 harbor the CTL precursors against myeloma cells. Thus
